Nelson Vergel
Founder, ExcelMale.com
Breast cancer is the most prevalent form of cancer in women worldwide. The medications and hormone therapies used to treat breast cancer can result in several side effects, usually due to modification of estrogen production in the body. Similar to the consequences of decreased estrogen production in women going through menopause, breast cancer patients undergoing hormone therapy can experience musculoskeletal symptoms such as joint pain, stiffness, bone pain, muscle pain and muscle weakness.
Aromatase inhibitors (AI) suppress estrogen levels in postmenopausal women with breast cancer by inhibiting the enzyme that activates estrogen production in fat tissue. Letrozole is a type of AI used in breast cancer hormone therapy treatment. Previous studies have shown that musculoskeletal symptoms worsened in patients taking letrozole as a result of vitamin D deficiency and decreased estrogen production. Researchers conducted a recent study to investigate the role that vitamin D3 and calcium supplementation might have on musculoskeletal symptoms in breast cancer patients taking letrozole.
http://www.vitamindcouncil.org/blog...patients/?mc_cid=a3ae68c086&mc_eid=41f41562a9
Aromatase inhibitors (AI) suppress estrogen levels in postmenopausal women with breast cancer by inhibiting the enzyme that activates estrogen production in fat tissue. Letrozole is a type of AI used in breast cancer hormone therapy treatment. Previous studies have shown that musculoskeletal symptoms worsened in patients taking letrozole as a result of vitamin D deficiency and decreased estrogen production. Researchers conducted a recent study to investigate the role that vitamin D3 and calcium supplementation might have on musculoskeletal symptoms in breast cancer patients taking letrozole.
http://www.vitamindcouncil.org/blog...patients/?mc_cid=a3ae68c086&mc_eid=41f41562a9
